|1.||Tian, Defeng: 1 article (06/2008)|
|2.||Wang, Liangyou: 1 article (06/2008)|
|3.||Sloper, Daniel T: 1 article (06/2008)|
|4.||Xing, Chengguo: 1 article (06/2008)|
|5.||Slaton, Joel W: 1 article (06/2008)|
|6.||Addo, Sadiya N: 1 article (06/2008)|
06/01/2008 - "The selective toxicity of WL-276 against drug-resistant PC-3 cells and its in vivo suppression of PC-3 prostate tumor growth suggest that WL-276 is a promising lead candidate for the development of Bcl-2 antagonists against drug-resistant HRPC."
06/01/2008 - "The anticancer activity of WL-276 was manifested in its suppression of PC-3-induced prostate tumor growth in vivo. "
06/01/2008 - "In addition, three PC-3 cell lines with acquired drug resistance against standard cancer chemotherapies were more sensitive to WL-276 than the parent PC-3 cell line. "
06/01/2008 - "WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth."
|1.||Proteins (Proteins, Gene)
|1.||Drug Therapy (Chemotherapy)